Boston Scientific agrees to acquire Penumbra for fourteen billion dollars in neurovascular market return
Boston Scientific announced a $14.5 billion deal to acquire Penumbra on Thursday. The move marks a strategic return to the neurovascular market segment.
Insights:
Boston Scientific Corporation has agreed to acquire Penumbra Inc. for $14.5 billion in a transaction announced on January 15, 2026. This acquisition is the first major deal in the healthcare sector for the year and represents the second-largest takeover ever for the Boston Scientific Corporation. The purchase price is set at $374 per share, which provides a 19.3% premium to the last closing price of Penumbra Inc.. Under the terms of the agreement, Penumbra Inc.shareholders can elect to receive either $374 in cash or 3.8721 shares of Boston Scientific Corporationfor each share held.
The strategic move marks a return for the Boston Scientific Corporationto the neurovascular market segment, an area it exited more than a decade ago when it divested its previous neurovascular business to the Stryker Corporation . Chief Executive Officer Mike Mahoney mike mahoneystated that the acquisition was a home run and described it as financially compelling. He noted that the company had long viewed the neurovascular field as attractive and intended to re-enter with a scaled commercial platform and a strong product pipeline. The transaction is expected to be completed in 2026.
